The RESCEU project aims to develop robust evidence on respiratory syncytial virus (RSV) disease burden and economic impact in Europe and provide infrastructure to perform future pivotal clinical trials for RSV vaccines and therapeutics. HTML Image Summary (Research in a nutshell)Human respiratory syncytial virus (RSV) is a viral infection which can cause severe respiratory disease in the very young, elderly and in high risk groups such as premature babies or adults with chronic obstructive lung disease.RESCEU project is an Innovative Medicines Initiative (IMI) funded project under the EU’s Horizon 2020 programme and has been funded for 5 years from 2017 to 2021. It comprises six work packages.Using a multidisciplinary and international approach, RESCEU brings together clinicians, epidemiologists, scientists, health economists, statisticians, public health professionals, patient organisations, regulatory agencies and industry to address key gaps in knowledge of RSV. The project is timely given the many RSV vaccines and therapeutics currently under development.Key PeopleNameRoleProfessor Harish NairProfessor of Paediatric Infectious Diseases and Global Health, Project CoordinatorProfessor Harry CampbellProfessor of Genetic Epidemiology and Public HealthRachel ReevesResearch FellowTing ShiResearch FellowAnne DouglasResearch FellowStephanie ScottResearch AssistantYou LiPhD studentProfessor Steve CunninghamProfessor of Paediatric Respiratory Medicine (based in Centre for Inflammation Research)Professor Debby BogaertScottish Senior Clinical Fellow and Honorary Consultant in paediatric infectious diseases (based in Centre for Inflammation Research)ContactProfessor Harish Nair: harish.nair@ed.ac.ukWebsitewww.resc-eu.orgKey publicationsNo publications yet.Key CollaborationsECDC (European Centre for Disease Control)WHO (World Health Organisation)GIHSN (Global Influenza Hospitalisation Surveillance Network)RSV GEN (RSV Global Epidemiology Network)ReSViNet (Respiratory Syncytial Virus Network)PartnersUniversity of Antwerp, BelgiumUniversity Medical Centre Utrecht, NetherlandsUniversity of Oxford, UKSynapse Research Management Partners S.L, SpainImperial College of Science, Technology and Medicine, UKServicio Galego de Saúde, SpainVarsinais-Suomen sairaanhoitopiirin kuntayhtymä, FinlandRijksinstituut voor Volksgezondheid en Milieu (National Institute for Public Health and the Environment), NetherlandsStatens Serum Institut, DenmarkAcademisch Ziekenhuis Groningen, NetherlandsFondazione PENTA, ItalyAstraZeneca ABPfizer LimitedGlaxoSmithKline Biologicals SASanofi PasteurJanssen Pharmaceutica NVNovavax Inc.FundersInnovative Medicines Initiative 2 Joint UndertakingEuropean Union’s Horizon 2020 research and innovation programme and EFPIA (Grant no. 1156019)TimelineJanuary 2017- December 2021 Scientific themesRespiratory Syncytial Virus, respiratory infections, epidemiology, burden of disease, clinical trialsMethodology keywordsSystematic review, clinical trial, biobank, record-linkage, epidemiology, health economics, modelling This article was published on 2024-09-24
HTML Image Summary (Research in a nutshell)Human respiratory syncytial virus (RSV) is a viral infection which can cause severe respiratory disease in the very young, elderly and in high risk groups such as premature babies or adults with chronic obstructive lung disease.RESCEU project is an Innovative Medicines Initiative (IMI) funded project under the EU’s Horizon 2020 programme and has been funded for 5 years from 2017 to 2021. It comprises six work packages.Using a multidisciplinary and international approach, RESCEU brings together clinicians, epidemiologists, scientists, health economists, statisticians, public health professionals, patient organisations, regulatory agencies and industry to address key gaps in knowledge of RSV. The project is timely given the many RSV vaccines and therapeutics currently under development.Key PeopleNameRoleProfessor Harish NairProfessor of Paediatric Infectious Diseases and Global Health, Project CoordinatorProfessor Harry CampbellProfessor of Genetic Epidemiology and Public HealthRachel ReevesResearch FellowTing ShiResearch FellowAnne DouglasResearch FellowStephanie ScottResearch AssistantYou LiPhD studentProfessor Steve CunninghamProfessor of Paediatric Respiratory Medicine (based in Centre for Inflammation Research)Professor Debby BogaertScottish Senior Clinical Fellow and Honorary Consultant in paediatric infectious diseases (based in Centre for Inflammation Research)ContactProfessor Harish Nair: harish.nair@ed.ac.ukWebsitewww.resc-eu.orgKey publicationsNo publications yet.Key CollaborationsECDC (European Centre for Disease Control)WHO (World Health Organisation)GIHSN (Global Influenza Hospitalisation Surveillance Network)RSV GEN (RSV Global Epidemiology Network)ReSViNet (Respiratory Syncytial Virus Network)PartnersUniversity of Antwerp, BelgiumUniversity Medical Centre Utrecht, NetherlandsUniversity of Oxford, UKSynapse Research Management Partners S.L, SpainImperial College of Science, Technology and Medicine, UKServicio Galego de Saúde, SpainVarsinais-Suomen sairaanhoitopiirin kuntayhtymä, FinlandRijksinstituut voor Volksgezondheid en Milieu (National Institute for Public Health and the Environment), NetherlandsStatens Serum Institut, DenmarkAcademisch Ziekenhuis Groningen, NetherlandsFondazione PENTA, ItalyAstraZeneca ABPfizer LimitedGlaxoSmithKline Biologicals SASanofi PasteurJanssen Pharmaceutica NVNovavax Inc.FundersInnovative Medicines Initiative 2 Joint UndertakingEuropean Union’s Horizon 2020 research and innovation programme and EFPIA (Grant no. 1156019)TimelineJanuary 2017- December 2021 Scientific themesRespiratory Syncytial Virus, respiratory infections, epidemiology, burden of disease, clinical trialsMethodology keywordsSystematic review, clinical trial, biobank, record-linkage, epidemiology, health economics, modelling
